- 1 Title: Association of coffee consumption in metabolic syndrome: a cross-sectional and
- 2 Mendelian randomization study in UK Biobank
- 3 Tommy Hon Ting Wong^{1,2}, Shan Luo², Shiu Lun Au Yeung², Jimmy Chun Yu Louie^{1,3}
- 4
- 5 Affiliations:
- 6 1. School of Biological Sciences, Faculty of Science, The University of Hong Kong
- 7 2. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- 8 3. Department of Nursing and Allied Health, School of Health Sciences, Swinburne University
- 9 of Technology, Melbourne, Australia
- 10 Corresponding author: Dr. Jimmy Chun Yu Louie
- 11 Address: Department of Nursing and Allied Health, School of Health Sciences, Swinburne
- 12 University of Technology, Melbourne, Australia
- 13 Email: jimmylouie@swin.edu.au
- 14 Tel: +61 3 9214 3504
- 15
- 16 Funding information: This study was supported by an internal grant from the Faculty of
- 17 Science, The University of Hong Kong.
- 18 **Conflict of interest:** None declared.
- 19
- 20 Abstract: 246
- 21 Main text: 3,051
- 22

23 Abstract

Objective: To investigate the associations between coffee consumption and metabolic syndrome and its component conditions, as well as the effect of using milk, sugar, and artificial sweetener on these associations.

Research Design and Methods: The cross-sectional analysis included 351,805 participants from the UK Biobank. Coffee consumption data was obtained using food frequency questionnaire and 24-hour recall and metabolic syndrome was ascertained based on blood biochemistry results and self-reported medication use. Odds ratios were calculated using multivariable logistic regression adjusted for lifestyle and socioeconomic factors, with verification using two-sample Mendelian randomization.

33 **Results**: Coffee consumption up to 2 cups per day was inversely associated with metabolic 34 syndrome (1 cup/day, OR: 0.88, 95% CI: 0.85, 0.92; 2 cups/day, OR: 0.90, 95% CI: 0.86, 0.93) 35 while associations at higher intakes were near null. Mendelian randomization did not support a 36 causal association between coffee intake and metabolic syndrome. Both self-reported and 37 genetically predicted high coffee consumption (4 cups per day or more) were associated with 38 central obesity. The inverse association between coffee consumption and metabolic syndrome 39 was more profound among drinkers of ground coffee than those of instant coffee. Results were 40 similar when stratified by the use of milk and sugar, yet the use of artificial sweetener with 41 coffee was positively associated with metabolic syndrome and all component conditions.

42 Conclusions: Coffee consumption likely increase the risk of central obesity but unlikely impact
43 risk of metabolic syndrome. The possible health effect of using artificial sweetener with coffee
44 warrant investigations in future studies.

- 45 Keywords: coffee, metabolic syndrome, Mendelian randomization, milk, sugar, artificial
- 46 sweetener

48 Introduction

49 Metabolic syndrome is a condition that involves the co-occurrence of multiple metabolic 50 abnormalities, including high fasting blood glucose level, dyslipidemia, high blood pressure, and 51 central obesity (1). Patients meeting the criteria of metabolic syndrome had higher risks of 52 developing type 2 diabetes (2) and cardiovascular diseases (3). Given metabolic syndrome was 53 estimated to be affecting 20 - 30% of the global population (4-7) and is a known risk factor for 54 type 2 diabetes (2) and cardiovascular diseases (3), identifying modifiable factors contributing to 55 increased risk of metabolic syndrome would be of great public health interest.

56

A recent systematic review of cross-sectional studies suggested an inverse relationship between 57 58 coffee consumption and metabolic syndrome (8). Possible mechanisms may include an 59 improvement in energy balance which was contributed by caffeine intake (9), as well as 60 antioxidative and anti-inflammatory effects associated with polyphenols in coffee (10). However, 61 our recent meta-analysis (8) found that coffee consumption was not longitudinally associated 62 with metabolic syndrome. These are also consistent with randomized controlled trials (RCTs) showing habitual coffee consumption did not affect blood glucose and lipid levels (11; 12), 63 64 which indirectly suggest previous observational studies may be confounded by 65 sociodemographic factors or reverse causation. Nevertheless, it remains possible that the effect of coffee with metabolic syndrome may differ by coffee subtypes or how the coffee was being 66 67 prepared (e.g. the use of milk and sweetener).

68

The primary aim of this study is to assess the cross-sectional association of overall coffeeconsumption in metabolic syndrome and its components (i.e., high fasting blood glucose, high

triglycerides, central obesity, high blood pressure, and low high-density-lipoprotein-cholesterol (HDL-cholesterol) using a large population-based study. We also conducted a Mendelian randomization study, which used genetic variants allocated at conception and hence less vulnerable to confounding, to verify the observational association (13). The secondary aims were to investigate the association of coffee consumption in metabolic syndrome differed by coffee types and the use of milk, sugar, and artificial sweetener.

77

78 **Research Design and Methods**

79 The UK Biobank

80 The UK Biobank is a large-scale prospective cohort aiming to improve the understanding of the 81 prevention, diagnosis, and treatment of a wide range of common and life-threatening diseases in middle to old-aged people. The design and the protocol of this project has been previously 82 83 published (14; 15). In brief, approximately 500,000 participants with 40 - 69 years of age living 84 in the United Kingdom were recruited during 2006 – 2010. Data regarding demographics, 85 socioeconomic status, health, and diet were collected in 22 assessment centers across the United 86 Kingdom and blood samples were also taken for biochemical analyses. All UK Biobank 87 participants were genotyped using either the Affymetrix UK BiLEVE Axiom or Affymetrix UK 88 Biobank Axiom array. The UK Biobank project was approved by the National Information 89 Governance Board for Health and Social Care and the NHS North West Multicenter Research 90 Ethics Committee (reference number: 11/NW/0382). Written consent was obtained from all 91 participants.

93 Habitual coffee intake

94 Participants were asked "How many cups of coffee do you drink each day (include decaffeinated coffee)?" and they were prompted to enter their average amount of consumption over the last 95 96 year in positive integers in a food frequency questionnaire (FFQ). Participants were also asked to 97 select the type of coffee that they used to drink at that time and available responses included 98 "decaffeinated coffee", "instant coffee", "ground coffee (include espresso, filter etc.)", and 99 "other type of coffee". Participants recruited during 2009-2010 also filled in a detailed 24-hour 100 recall dietary questionnaire in addition to the FFQ. In the 24-hr recall questionnaire they were 101 asked "Did you drink any coffee yesterday?" with a "Yes/No" option. For those who selected 102 "Yes" they were further asked for their consumption (in cups or mugs) of different types of 103 coffee on the previous day. Available options for coffee types included instant coffee, filtered 104 coffee, cappuccino, latte, espresso, decaffeinated coffee, and other coffee types. Participants also 105 reported whether they added milk to instant and filtered coffee, as well as sugar or artificial 106 sweetener (in teaspoon) when drinking coffee in general.

107

108 Outcomes

The primary outcome was metabolic syndrome, which was defined by the International Diabetes Federation in 2009 (1) as having any 3 of the following: high fasting glucose, high triglycerides, central obesity, high blood pressure, and low HDL-cholesterol (secondary outcomes). The detailed criteria for each condition was listed in **Supplemental Table 1**. Waist circumference was measured in cm using a measurement tape (SECA). Blood pressure (mmHg) was measured twice using the IntelliSense blood pressure monitor model HEM-907XL (Omron) for each participant and the average of the two measurements were used in this study. Serum levels of

glucose (mmol/L), triglycerides (mmol/L), and HDL-cholesterol (mmol/L) were all measured using the Beckman Coulter AU5800 platform. Medications for treating abnormal levels of glucose, lipids, and blood pressure were self-reported and the corresponding medication code were shown in **Supplemental Table 2**. The details of case and control ascertainment and handling of missing data was stated in **Supplemental Information**.

121

122 Potential confounders

We considered age, sex, socioeconomic position (Townsend Deprivation index, and highest qualification obtained), lifestyle factors (smoking status, alcohol intake frequency, physical activity, and intakes of fruit, vegetable, and tea) as possible confounders. Details of measurement were provided in the **Supplemental Information**.

127

128 Genetic predictors of coffee consumption

Genetic predictors of coffee consumption, i.e., single nucleotide polymorphisms (SNPs), were retrieved from a genome-wide association study (GWAS) of predominantly European ancestry in the Coffee and Caffeine Genetics Consortium (CCGC) (16). These included (i) coffee consumption in cups per day among coffee drinkers (phenotype 1, n = 129,488) and (ii) no/low versus high coffee consumption (phenotype 2, n = 65,842). Only independent SNPs ($r^2 < 0.001$) that were genome-wide significant ($p < 5 \times 10^{-8}$) in the trans-ethnic meta-analysis were selected.

135

136 Genetic associations of the outcomes

137 The genetic associations between the SNPs identified for cups of coffee consumed (phenotype 1)

138 and being a coffee drinker (phenotype 2) with metabolic syndromes and its components were

obtained from the UK Biobank participants of European ancestry. The genetic associations of outcomes were obtained using multivariable logistic regression, adjusted for age, sex, top 20 principal components, genotype array, and assessment center. Participants with poor quality genotyping (missing rate > 0.01), \geq 10 putative third-degree relatives, with sex chromosome aneuploidy, with a mismatch between genetic sex and reported sex, and those with a mismatch in reported ethnicity and genetic ethnicity were excluded. Up to 360,903 participants provided data for the genetic associations of outcomes.

146

147 *Statistical analyses*

148 Cross sectional analyses

149 We assessed the cross-sectional associations of coffee consumption in metabolic syndrome and 150 its components using multivariable logistic regressions with zero consumers as the reference 151 group. Effect estimates were adjusted for potential confounders (age, sex, Townsend deprivation 152 index, highest qualification attained, smoking status, alcohol intake frequency, physical activity 153 level, fruit intake, vegetable intake, and tea consumption). We also included coffee type as a 154 covariate when analyzing data collected from 24-hour recalls. To investigate the association 155 between using milk, sugar, and artificial sweetener with coffee and all outcomes, we stratified 156 the main analyses by these factors whenever possible. Stratification by milk use was carried out 157 for instant and filtered coffee, while stratification by use of sugar and artificial sweetener was 158 also carried out for all coffee types except espresso due to a lack of cases.

159

160 Mendelian randomization analysis

We calculated the R^2 (only phenotype 1) and F statistics of the instruments as an indicator of 161 162 instrument strength based on equations used in a previous Mendelian randomization study (17), 163 where a higher F statistic indicated lower evidence for weak instrument bias. Effect alleles of all 164 instruments were aligned to the coffee consumption-increasing allele. We assessed the causal 165 association of coffee consumption in metabolic syndrome and its component conditions using 166 inverse variance weighted (IVW) with multiplicative random effect models. The IVW estimator 167 assumes balanced horizontal pleiotropy (18) and high heterogeneity among instrument-specific 168 Wald Ratios based on Cochran's Q test may imply the inclusion of invalid instruments. To assess 169 the robustness of our findings, we also conducted a range of sensitivity analyses which were 170 based on different assumptions. The MR-Egger estimator allows for overall directional 171 pleiotropic effects by assuming the instrument strength is independent of the direct effect 172 (InSIDE assumption). An MR-Egger intercept with a p-value < 0.05 reflects the presence of 173 horizontal pleiotropic effect (18). The weighted median method assumes at least 50% of the 174 weight come from valid SNPs (19). Since smoking status and alcohol consumption were well-175 recognized confounding factors in the associations between coffee consumption and various 176 health outcomes (20) and genetic predictors of coffee consumption were found to be associated 177 with both traits as well (20) we conducted multivariable MR to obtain effect estimates adjusted 178 for alcohol consumption and liability to smoking initiation. Details regarding the multivariable 179 Mendelian randomization analysis was provided in the **Supplemental Information**.

To correct for multiple testing, the *p*-value threshold for statistical significance for all analyses
was set at 0.0083 (0.05 divided by 6 outcomes).

183

184 **Results**

185 Participant characteristics

Participants who had withdrawn, were not British, without coffee consumption data, and without data on any confounding variables were excluded from all analyses. Those with missing individual outcome variables were excluded from the corresponding analyses. The detail exclusion flowchart was shown in **Figure 1**. The characteristics of all included participants (n =351,805) were shown in **Table 1**. Participants who consumed coffee were more likely to be male, more likely to be current smoker, consumed alcohol more frequently, had higher education attainment, and drank less tea.

193

194 Association of coffee consumption and metabolic syndrome, and its components

195 Figure 2 shows the association between consuming cups of coffee per day and metabolic 196 syndrome amongst 142,594 participants, after controlling for potential confounders. Participants 197 consuming up to 3 cups of coffee per day were less likely to have metabolic syndrome when 198 compared with coffee abstainers (<1 cup per day, OR: 0.91, 95% CI: 0.87, 0.96; 1 cup per day, 199 OR: 0.88, 95% CI: 0.85, 0.92; 2 cups per day, OR: 0.90, 95% CI: 0.86, 0.93; 3 cups per day, OR: 200 0.94, 95% CI: 0.90, 0.99). However, consuming 4 cups of coffee or more per day was potentially 201 associated with higher odds of having metabolic syndrome (4 cups per day, OR: 1.03, 95% CI: 202 0.98, 1.08; 5 cups per day, OR: 1.06, 95% CI: 0.99, 1.12; 6 cups per day, OR: 1.05, 95% CI: 0.99, 203 1.11). Coffee consumption was also positively associated with high fasting glucose and high

triglycerides, but inversely associated with having high blood pressure and low HDL-cholesterol
(Figure 2). The association between coffee consumption and central obesity was J-shaped.

206

Using Mendelian randomization (8 instruments for cups of coffee consumed: R^2 : 0.4%. F 207 208 statistics: 56.1, and the range of F statistics for the 3 instruments for liability to high coffee 209 consumption: 44.4 - 100.0) (Supplemental Table 3), we did not identify any association of 210 these two coffee phenotypes with risk of metabolic syndrome using IVW (Figure 3). Although 211 the instruments were heterogenous based on Cochran's Q, there was no strong evidence for 212 overall horizontal pleiotropy based on MR-Egger intercept (Supplemental Tables 4 and 5). 213 Adjusting for the liability to smoke initiation and alcohol consumption did not lead to material 214 changes in the results (Supplemental Tables 6 - 9). However, both coffee phenotypes were 215 associated with higher risk of central obesity, with directionally consistent findings from the 216 sensitivity analyses (Figure 3). After adjusting for genetic liabilities to smoking initiation and 217 alcohol consumption, results of both phenotypes were similar to those of the univariate MR. 218 There was suggestive evidence that both phenotypes were associated with higher risk of high 219 fasting glucose, but not high triglycerides, high blood pressure and low HDL-cholesterol (Figure 220 3).

221

Association of coffee subtypes, the use of sugar/milk, in metabolic syndrome and its components
The directions of associations observed among drinkers of instant coffee, ground coffee, and
decaffeinated coffee mostly aligned with those of the main results with a few exceptions (Figure
For instance, null associations were observed between instant coffee intake with metabolic
syndrome and high blood pressure, as well as between decaffeinated coffee intake and low HDL-

227 cholesterol. Latte and cappuccino intake was inversely associated with metabolic syndrome and 228 high blood pressure only, while all associations for espresso intake were near null 229 (**Supplemental Figures 1 – 2**).

230

Results of analysis stratified by use of milk, sugar, and artificial sweetener were shown in
Supplemental Figures 1 – 4. Stratifying by milk use did not affect any of the associations.
Sugar use was inversely associated with high fasting glucose and central obesity among drinkers
of instant coffee but not other coffee types.

235

Artificial sweetener use was positively associated with all outcomes among instant coffee consumers. Similarly, filtered coffee intake with artificial sweetener was positively associated with all outcomes except high fasting glucose and high triglycerides. Avoidance of artificial sweetener was inversely associated with metabolic syndrome, central obesity, and low HDLcholesterol among filtered coffee drinkers, as well as metabolic syndrome and high blood pressure among latte and cappuccino drinkers.

242

243 Discussion

In this large population-based study, we found habitual coffee consumption at 1-3 cups per day was associated with lower risk of metabolic syndrome. However, these associations were not replicated using Mendelian randomization, implying possible confounding in the observational analyses. We also observed that only ground and decaffeinated coffee intakes were inversely associated with metabolic syndrome, while a null association was observed among instant coffee drinkers. Moreover, we showed for the first time in Europeans that while milk and sugar use did

not substantially affect the association between coffee intake and metabolic syndrome, the use of artificial sweetener was positively associated with metabolic syndrome and all component conditions among both instant and filtered coffee drinkers.

253

254 Our study was consistent with a previous smaller Danish study which also showed an inverse observational association of coffee consumption in metabolic syndrome but not in Mendelian 255 256 randomization (21). As such, the inverse association observed in previous studies (22; 23) could 257 possibly be due to residual confounding, such as variation in diet quality (24). However, we also 258 observed a positive association of coffee consumption in central obesity in the observational and 259 genetic analyses, a finding that was in line with a previous one-sample Mendelian randomization 260 study (25) that observed a positive association between coffee consumption and obesity, but 261 inconsistent with previous observational studies (26). The bioactive components in coffee 262 unlikely explained this association, since caffeine consumption may enhance lipolysis and food-263 induced thermogenesis (27), while evidence regarding the effect of polyphenols found in coffee 264 on preventing obesity have been inconsistent (28). Furthermore, a recent longitudinal study 265 observed a mild association between habitual coffee consumption and waist circumference 266 reduction (29). One possible cause behind our findings could be psychological stress, which is a 267 well-known factor of obesity (30). Evidence from observational studies supported a positive 268 association between caffeine intake and psychological stress (31; 32). Although cortisol, which 269 was an established marker for psychological stress, was found to be causally unrelated to waist-270 to-hip ratio and body-mass-index (33), the authors acknowledged that genetically predicted 271 cortisol may not be a direct reflection of stress, which would induce other biological responses 272 other than cortisol elevation, such as the release of inflammatory cytokines (34). Further studies

are warranted to investigate if psychological stress is in the same causal pathway as coffee intakeand central obesity.

275

276 One novel aspect of this study was to explore the role of additives in the relation of coffee 277 consumption in metabolic syndrome, where we showed the use of artificial sweeteners were 278 associated with metabolic syndrome and all component conditions. There were reports linking 279 artificial sweetener use with increased caloric intake, worsened glycemic control, long-term 280 weight gain, and metabolic syndrome (35). One possible mechanism behind our finding is that 281 since sweet taste is treated by the brain as a signal of incoming caloric content, the lack of energy 282 in the artificial sweetener would weaken this perception, leading to dysregulation in nutrient 283 signaling and subsequent homeostasis (36). Another proposed mechanism is that artificial 284 sweetener intake could alter the microbiota composition in human gut, thereby inducing glucose 285 intolerance (37). Nonetheless, while the evidence regarding the effect of artificial sweetener use 286 on weight management and glycemic control was highly mixed (38; 39), our findings could be 287 also explained by reverse causation where they used artificial sweeteners because of their poor 288 metabolic health. Further longitudinal studies are needed to determine if the use of sugar and 289 artificial sweeteners augments the association between coffee consumption and metabolic 290 syndrome.

291

Strengths of this study include large sample size and the use of different approaches to interrogate the role of coffee consumption in metabolic syndrome, as well as the role of additives. Nevertheless, several limitations of this analysis should be acknowledged. First, the definitions of metabolic syndrome used in this study required fasting measurement of biomarkers, thus a

296 portion of the participants had to be excluded from the analyses of certain outcomes and the 297 results may possibly be affected by selection bias. Second, some analyses that were stratified by 298 use of sugar and artificial sweetener were left with very few cases, thus the statistical power of 299 such tests could be limited. Third, although we corrected for possible horizontal pleiotropy via 300 alcohol and tobacco use using multivariable Mendelian randomization, the genetic instruments 301 used in this analysis were also associated with tea consumption, as shown in a previous study 302 (20), and hence may be biased by horizontal pleiotropy although the findings were generally 303 consistent in other sensitivity analyses which were more robust to violation via horizontal 304 pleiotropy, such as MR-Egger. Fourth, the use of a dichotomized exposure variable (phenotype 2) 305 could possibly violate the instrumental variable assumption of MR (40). Finally, results from this 306 study may not be generalizable to populations of non-European ancestry because the data used in 307 this study were collected from participants of European origin only.

308

309 To conclude, low-to-moderate coffee intake (1-3 cups per day) was associated with lower risk of 310 metabolic syndrome in cross-sectional analyses, but such associations were not supported by 311 Mendelian randomization. However, high coffee consumption may contribute to higher risk of 312 central obesity. Our findings also highlighted the variation in results due to coffee types and use 313 of sugar and artificial sweeteners. Nonetheless, the findings should be verified in future 314 longitudinal studies with data in coffee consumption and use of coffee additives, while the causal 315 relationship between coffee intake and metabolic health outcomes should be verified in future 316 Mendelian randomization studies involving more genetic instruments for coffee consumption.

317

318 Data availability

319 The data used in this study can be requested via application to UK Biobank 320 (https://www.ukbiobank.ac.uk).

321

322 Acknowledgement

- 323 The present study was conducted under UK Biobank application number 44407.
- 324 Authors' contributions: JCYL and TWHT designed research; SL, AYSL, and JCYL provided
- 325 essential materials; TWHT analyzed the data, performed statistical analysis, and drafted the
- 326 paper; all authors critically evaluated and amended the manuscript. TWHT and JCYL had
- 327 primary responsibility for the final content. All authors read and approved the final manuscript.

328 **Reference**

- 329 1. Alberti KGMM, Eckel Robert H, Grundy Scott M, Zimmet Paul Z, Cleeman James I, Donato
- 330 Karen A, Fruchart J-C, James WPT, Loria Catherine M, Smith Sidney C: Harmonizing the
- 331 Metabolic Syndrome. Circulation 2009;120:1640-1645
- 332 2. DeBoer MD, Filipp SL, Gurka MJ: Use of a Metabolic Syndrome Severity
- 333 Z Score to Track Risk During Treatment of Prediabetes: An Analysis of
- the Diabetes Prevention Program. Diabetes Care 2018;41:2421
- 335 3. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL,
- 336 Eisenberg MJ: The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and
- 337 Meta-Analysis. Journal of the American College of Cardiology 2010;56:1113-1132
- 4. Hirode G, Wong RJ: Trends in the Prevalence of Metabolic Syndrome in the United States,
- 339 2011-2016. JAMA 2020;323:2526-2528
- 5. Tanamas SK, Magliano DJ, Lynch B, Sethi P, Willenberg L, Polkinghorne KR, Chadban S,
- 341 Dunstan D, JE S: AusDiab 2012. The Australian Diabetes, Obesity and Lifestyle Study.
 342 Melbourne, 2013
- 343 6. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Raso FUM, Muiesan ML,
- 344 Ryliškytė L, Rietzschel E, Strait J, Vlachopoulos C, Völzke H, Lakatta EG, Nilsson PM, for the
- 345 Metabolic S, Arteries Research C: Metabolic syndrome across Europe: Different clusters of risk
- 346 factors. European Journal of Preventive Cardiology 2015;22:486-491
- 347 7. Liu B, Chen G, Zhao R, Huang D, Tao L: Temporal trends in the prevalence of metabolic
- 348 syndrome among middle-aged and elderly adults from 2011 to 2015 in China: the China health
- and retirement longitudinal study (CHARLS). BMC Public Health 2021;21:1045

- 350 8. Wong THT, Wong CH, Zhang X, Zhou Y, Xu J, Yuen KC, Wan JMF, Louie JCY: The
- 351 Association Between Coffee Consumption and Metabolic Syndrome in Adults: A Systematic
- 352 Review and Meta-Analysis. Advances in Nutrition 2021;12:708-721
- 353 9. Harpaz E, Tamir S, Weinstein A, Weinstein Y: The effect of caffeine on energy balance.
- Journal of Basic and Clinical Physiology and Pharmacology 2017;28:1-10
- 355 10. van Dam RM, Hu FB, Willett WC: Coffee, Caffeine, and Health. New England Journal of
 356 Medicine 2020;383:369-378
- 357 11. Alperet DJ, Rebello SA, Khoo EY-H, Tay Z, Seah SS-Y, Tai B-C, Tai ES, Emady-Azar S,
- 358 Chou CJ, Darimont C, van Dam RM: The effect of coffee consumption on insulin sensitivity and
- 359 other biological risk factors for type 2 diabetes: a randomized placebo-controlled trial. The
- 360 American Journal of Clinical Nutrition 2020;111:448-458
- 361 12. Du Y, Lv Y, Zha W, Hong X, Luo Q: Effect of coffee consumption on dyslipidemia: A meta-
- analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases2020;30:2159-2170
- 364 13. Davies NM, Holmes MV, Davey Smith G: Reading Mendelian randomisation studies: a
 365 guide, glossary, and checklist for clinicians. BMJ 2018;362:k601
- 366 14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J,
- 367 Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T,
- 368 Collins R: UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range
- 369 of Complex Diseases of Middle and Old Age. PLOS Medicine 2015;12:e1001779
- 370 15. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
- 371 Delaneau O, O'Connell J, Cortes A, Welsh S, McVean G, Leslie S, Donnelly P, Marchini J:
- 372 Genome-wide genetic data on ~500,000 UK Biobank participants. bioRxiv 2017:166298

373	16. Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N,
374	Fischer K, Renstrom F, Ngwa JS, Huikari V, Cavadino A, Nolte IM, Teumer A, Yu K, Marques-
375	Vidal P, Rawal R, Manichaikul A, Wojczynski MK, Vink JM, Zhao JH, Burlutsky G, Lahti J,
376	Mikkilä V, Lemaitre RN, Eriksson J, Musani SK, Tanaka T, Geller F, Luan J, Hui J, Mägi R,
377	Dimitriou M, Garcia ME, Ho WK, Wright MJ, Rose LM, Magnusson PKE, Pedersen NL,
378	Couper D, Oostra BA, Hofman A, Ikram MA, Tiemeier HW, Uitterlinden AG, van Rooij FJA,
379	Barroso I, Johansson I, Xue L, Kaakinen M, Milani L, Power C, Snieder H, Stolk RP,
380	Baumeister SE, Biffar R, Gu F, Bastardot F, Kutalik Z, Jacobs DR, Forouhi NG, Mihailov E,
381	Lind L, Lindgren C, Michaëlsson K, Morris A, Jensen M, Khaw KT, Luben RN, Wang JJ,
382	Männistö S, Perälä MM, Kähönen M, Lehtimäki T, Viikari J, Mozaffarian D, Mukamal K, Psaty
383	BM, Döring A, Heath AC, Montgomery GW, Dahmen N, Carithers T, Tucker KL, Ferrucci L,
384	Boyd HA, Melbye M, Treur JL, Mellström D, Hottenga JJ, Prokopenko I, Tönjes A, Deloukas P,
385	Kanoni S, Lorentzon M, Houston DK, Liu Y, Danesh J, Rasheed A, Mason MA, Zonderman AB,
386	Franke L, Kristal BS, Karjalainen J, Reed DR, Westra HJ, Evans MK, Saleheen D, Harris TB,
387	Dedoussis G, Curhan G, Stumvoll M, Beilby J, Pasquale LR, Feenstra B, Bandinelli S, Ordovas
388	JM, Chan AT, Peters U, Ohlsson C, Gieger C, Martin NG, Waldenberger M, Siscovick DS,
389	Raitakari O, Eriksson JG, Mitchell P, Hunter DJ, Kraft P, Rimm EB, Boomsma DI, Borecki IB,
390	Loos RJF, Wareham NJ, Vollenweider P, Caporaso N, Grabe HJ, Neuhouser ML, Wolffenbuttel
391	BHR, Hu FB, Hyppönen E, Järvelin MR, Cupples LA, Franks PW, Ridker PM, van Duijn CM,
392	Heiss G, Metspalu A, North KE, Ingelsson E, Nettleton JA, van Dam RM, Chasman DI, The C,
393	Caffeine Genetics C, International Parkinson's Disease Genomics C, North American Brain
394	Expression C, Consortium UKBE: Genome-wide meta-analysis identifies six novel loci
395	associated with habitual coffee consumption. Molecular Psychiatry 2015;20:647-656

- 396 17. Au Yeung SL, Borges MC, Lawlor DA, Schooling CM: Impact of lung function on
 397 cardiovascular diseases and cardiovascular risk factors: a two sample bidirectional Mendelian
 398 randomisation study. Thorax 2021:thoraxinl-2020-215600
- 399 18. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J: A
- 400 framework for the investigation of pleiotropy in two-sample summary data Mendelian401 randomization. Statistics in Medicine 2017;36:1783-1802
- 402 19. Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent Estimation in Mendelian
- 403 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic
- 404 Epidemiology 2016;40:304-314
- 405 20. Taylor AE, Davey Smith G, Munafò MR: Associations of coffee genetic risk scores with
- 406 consumption of coffee, tea and other beverages in the UK Biobank. Addiction 2018;113:148-157
- 407 21. Nordestgaard AT, Thomsen M, Nordestgaard BG: Coffee intake and risk of obesity,
- 408 metabolic syndrome and type 2 diabetes: a Mendelian randomization study. International Journal
 409 of Epidemiology 2015;44:551-565
- 410 22. Grosso G, Stepaniak U, Micek A, Topor-Mądry R, Pikhart H, Szafraniec K, Pająk A:
- 411 Association of daily coffee and tea consumption and metabolic syndrome: results from the Polish
- 412 arm of the HAPIEE study. European Journal of Nutrition 2015;54:1129-1137
- 413 23. Micek A, Grosso G, Polak M, Kozakiewicz K, Tykarski A, Puch Walczak A, Drygas W,
- 414 Kwaśniewska M, Pająk A: Association between tea and coffee consumption and prevalence of
- 415 metabolic syndrome in Poland results from the WOBASZ II study (2013–2014). International
- 416 Journal of Food Sciences and Nutrition 2018;69:358-368

- 417 24. Wong THT, Sui Z, Rangan A, Louie JCY: Discrepancy in socioeconomic status does not
- 418 fully explain the variation in diet quality between consumers of different coffee types. European
- 419 Journal of Nutrition 2018;57:2123-2131
- 420 25. Nicolopoulos K, Mulugeta A, Zhou A, Hyppönen E: Association between habitual coffee
- 421 consumption and multiple disease outcomes: A Mendelian randomisation phenome-wide
- 422 association study in the UK Biobank. Clinical Nutrition 2020;39:3467-3476
- 423 26. Lee A, Lim W, Kim S, Khil H, Cheon E, An S, Hong S, Lee DH, Kang S-S, Oh H, Keum N,
- 424 Hsieh C-C: Coffee Intake and Obesity: A Meta-Analysis. Nutrients 2019;11
- 425 27. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jéquier E: Caffeine and
- 426 coffee: their influence on metabolic rate and substrate utilization in normal weight and obese
 427 individuals. The American Journal of Clinical Nutrition 1980;33:989-997
- 428 28. Tajik N, Tajik M, Mack I, Enck P: The potential effects of chlorogenic acid, the main
- 429 phenolic components in coffee, on health: a comprehensive review of the literature. European
- 430 Journal of Nutrition 2017;56:2215-2244
- 431 29. Larsen SC, Mikkelsen ML, Frederiksen P, Heitmann BL: Habitual coffee consumption and
- 432 changes in measures of adiposity: a comprehensive study of longitudinal associations.
- 433 International Journal of Obesity 2018;42:880-886
- 434 30. Tomiyama AJ: Stress and Obesity. Annual Review of Psychology 2019;70:703-718
- 435 31. Magalhães R, Picó-Pérez M, Esteves M, Vieira R, Castanho TC, Amorim L, Sousa M,
- 436 Coelho A, Fernandes HM, Cabral J, Moreira PS, Sousa N: Habitual coffee drinkers display a
- 437 distinct pattern of brain functional connectivity. Molecular Psychiatry 2021;26:6589-6598
- 438 32. Zunhammer M, Eichhammer P, Busch V: Sleep Quality during Exam Stress: The Role of
- 439 Alcohol, Caffeine and Nicotine. PLOS ONE 2014;9:e109490

- 440 33. Kwok MK, Kawachi I, Rehkopf D, Schooling CM: The role of cortisol in ischemic heart
- 441 disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: a bi-directional
- 442 Mendelian randomization study. BMC Medicine 2020;18:363
- 443 34. Ippoliti F, Canitano N, Businaro R: Stress and Obesity as Risk Factors in Cardiovascular
- 444 Diseases: A Neuroimmune Perspective. Journal of Neuroimmune Pharmacology 2013;8:212-226
- 445 35. Azad MB, Abou-Setta AM, Chauhan BF, Rabbani R, Lys J, Copstein L, Mann A, Jeyaraman
- 446 MM, Reid AE, Fiander M, MacKay DS, McGavock J, Wicklow B, Zarychanski R: Nonnutritive
- 447 sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized
- 448 controlled trials and prospective cohort studies. Canadian Medical Association Journal449 2017;189:E929
- 450 36. Swithers SE: Artificial sweeteners produce the counterintuitive effect of inducing metabolic
 451 derangements. Trends in Endocrinology & Metabolism 2013;24:431-441
- 452 37. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N,
- 453 Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal
- 454 E, Elinav E: Artificial sweeteners induce glucose intolerance by altering the gut microbiota.
- 455 Nature 2014;514:181-186
- 456 38. Kim Y, Keogh JB, Clifton PM: Non-nutritive Sweeteners and Glycaemic Control. Current
 457 Atherosclerosis Reports 2019;21:49
- 458 39. Pearlman M, Obert J, Casey L: The Association Between Artificial Sweeteners and Obesity.
- 459 Current Gastroenterology Reports 2017;19:64
- 40. Burgess S, Labrecque JA: Mendelian randomization with a binary exposure variable:
 interpretation and presentation of causal estimates. European Journal of Epidemiology
 2018;33:947-952

		Coffee consumption (cups/day)								
Variables	0	<1	1	2	3	4	5	6 or more		
Participants, n	72860	24309	71116	67516	44629	30940	18260	22175		
Age, years	55.5 (8.2)	56.4 (7.9)	57.3 (8.0)	57.2 (7.9)	57.0 (7.9)	56.6 (7.9)	56.0 (8.0)	55.6 (8.0)		
Male, %	43.5	47.0	45.2	48.1	49.9	52.2	54.2	55.6		
Smoking status, %										
Never	57.6	58.3	57.4	55.7	54.3	50.9	47.2	39.9		
Previous	33.2	34.2	35.7	36.1	36.6	37.4	37.2	35.9		
Current	9.2	7.5	6.9	8.2	9.0	11.7	15.6	24.1		
Alcohol consumption frequency, %										
Monthly or less	37.7	27.1	24.9	21.8	21.6	22.7	25.8	32.3		
Weekly	46.0	52.7	53.1	53.2	52.5	52.4	51.1	46.9		
Daily	16.3	20.2	22.0	25.0	25.8	24.8	23.1	20.8		
Fruit intake, tbsp	3.0 (2.5)	3.1 (2.4)	3.2 (2.5)	3.2 (2.5)	3.0 (2.4)	2.9 (2.3)	2.8 (2.4)	2.7 (2.6)		
Vegetable intake, tbsp	4.7 (3.3)	4.7 (3.0)	4.9 (3.0)	4.9 (3.0)	4.8 (3.0)	4.8 (3.1)	4.7 (3.1)	4.8 (3.5)		
Tea intake, cups/day	4.7 (3.3)	4.6 (2.8)	4.0 (2.5)	3.3 (2.4)	2.6 (2.2)	2.2 (2.3)	1.8 (2.5)	1.9 (3.3)		
IPAQ category, %										
Low	20.0	19.3	17.0	17.1	18.3	19.2	21.4	22.3		
Moderate	39.0	42.0	41.6	42.1	42.1	41.3	39.6	38.1		
High	41.0	38.7	41.4	40.8	39.6	39.5	39.0	39.6		
Highest qualification obtained	ed, %									
Below GCSE	26.1	18.2	21.3	18.6	18.1	20.2	20.6	23.9		
GCSE	24.7	21.8	21.5	21.3	20.9	22.0	22.8	24.1		
Advanced level	7.7	8.4	7.6	7.7	7.7	7.4	7.3	7.6		
Degree holder	41.6	51.6	49.7	52.4	53.3	50.4	49.4	44.5		

Table 1 – characteristics of participants included in cross-sectional analysis (n = 351,805)

Values are mean (SD) for age and percentages for count variables. Coffee consumption was analyzed as a categorical variable. GCSE, general certificate of secondary education. IPAQ, International Physical Activity Questionnaire.

Figure 1 – Participant exclusion flowchart for the cross-sectional analysis.



Figure 2 – Associations between overall coffee consumption, as well as stratified by coffee types, and metabolic syndrome, high fasting glucose, high triglycerides, central obesity, high blood pressure, and low HDL-cholesterol.



Error bars are 95% CI. All data used were from the baseline food frequency questionnaire. All effect estimates were adjusted for age, sex, smoking status, alcohol consumption frequency, highest qualification obtained, vegetable intake, fruit intake, tea intake, and physical activity level.

Figure 3 – Results of MR analysis between coffee intake and metabolic syndrome, high fasting glucose, high triglycerides, central obesity, high blood pressure, and low HDL-cholesterol.

Inter Norffee		Metaboli	syndrome						High fasti	ng glucose			
Control Contro Control Control	Method	No. of SNPs	OR (95% CI)	Ρ				Method	No. of SNPs	OR (95% CI)	Р		
m n <td< td=""><td>Coffee consumption (cups/day)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Coffee consumption (cups/day)</td><td></td><td></td><td></td><td></td><td></td></td<>	Coffee consumption (cups/day)							Coffee consumption (cups/day)					
http: 4 2.0.0000 6.0 4.0.0000 6.0 0.0.000 6.0 0.0.000 <td>IVW</td> <td>8</td> <td>1.14 (0.72,1.80)</td> <td>0.57</td> <td></td> <td></td> <td>-</td> <td>IVW</td> <td>8</td> <td>1.79 (0.94,3.41)</td> <td>0.078</td> <td></td> <td></td>	IVW	8	1.14 (0.72,1.80)	0.57			-	IVW	8	1.79 (0.94,3.41)	0.078		
where the set of	MR-Egger	8	2.23 (0.99,5.03)	0.10			•	MR-Egger	8	1.08 (0.28,4.24)	0.92		\longrightarrow
Mathematical Mathem	Weighted median	8	1.22 (0.97,1.53)	0.093		-8-		Weighted median	8	1.51 (1.05,2.18)	0.026		-
Number depined on the set of the set o	MVMR-IVW	19	1.11 (0.85,1.46)	0.44				MVMR-IVW	19	1.38 (1.10,1.72)	0.0047		
Likity bip define consignedMich is plot offer consignedMich is plot of mich is plot offer consignedMich is plot of mich is pl	MVMR-MR-Egger	19	1.86 (1.06,3.25)	0.030		-	-	MVMR-MR-Egger	19	1.24 (0.75,2.04)	0.41		-
NM3121210 <td>Liability to high coffee consumption</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Liability to high coffee consumption</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Liability to high coffee consumption							Liability to high coffee consumption					
Mathem 3 14 9.24 0.44 <	IVW	3	1.20 (0.97,1.49)	0.092		-8-		IVW	3	1.24 (1.00,1.53)	0.051		
Name Name <t< td=""><td>MR-Egger</td><td>3</td><td>1.14 (0.42,3.11)</td><td>0.84</td><td></td><td>-</td><td></td><td>MR-Egger</td><td>3</td><td>0.81 (0.44,1.49)</td><td>0.62</td><td></td><td></td></t<>	MR-Egger	3	1.14 (0.42,3.11)	0.84		-		MR-Egger	3	0.81 (0.44,1.49)	0.62		
MAR. MC MOREMAR. MC MORE<	Weighted median	3	1.22 (1.05,1.42)	0.011		-		Weighted median	3	1.20 (0.98,1.48)	0.077		
Non-basis <	MVMR-IVW	13	1.13 (1.00,1.27)	0.052		•		MVMR-IVW	13	1.21 (1.05,1.40)	0.0081	•	
	MVMR-MR-Egger	13	1.18 (0.98,1.42)	0.074		-		MVMR-MR-Egger	13	1.22 (0.99,1.51)	0.061	-	
Image: Part of the second				0	.20 .00	1.0 dds ratio	4.0					.20 1.0 Odds ratio	4.0
Note 'No d'N's (No d'N's (No d'N's) No d'N's (No d'N's (No d'N's) No d'N's (No d'N's)													
Contract or consumption (uppoint) Contract or consumption (uppoint) NM a 0.40 (0.00.00) 0.20 More than the tha	Method	High tri	OR (95% CI)	Р				Method	No. of SNPs	OR (95% CI)	Р		
NY a b	Coffee consumption (cups/day)							Coffee consumption (cups/day)					
Min-Egyer a 1.54 (0.52 , 0.5 a 1.54 (0.52 , 0.5 a 1.54 (0.52 , 0.5 a a Wighted media 1.0 1.75 (1.52 , 0.52 0.00 0.64 0.66 0.6	IVW	8	0.94 (0.30,3.00)	0.92		-		IVW	8	1.35 (1.10,1.65)	0.0039	-=-	
Water media δ 172 (13.26 0.02 \bullet $Mach Mark Legar\delta31 (13.160.16.77\bulletMAR-Mark Legar1021 (13.660.02\bulletMMark Mark Legar100.000.00\bullet\bulletMark Mark Legar321 (13.660.02\bulletMMark Mark Legar3101 (11.120.02\bullet\bulletMark Mark Legar3124 (13.660.02\bulletMMark Mark Legar3101 (11.120.02\bullet\bulletMark Mark Legar3124 (13.660.02\bulletMMark Mark Legar3101 (11.060.02\bullet\bulletMark Mark Legar3101 (10.160.02\bullet\bulletMMark Mark Legar3101 (10.160.02\bulletMark Mark Legar101 (10.160.02\bullet\bulletMMark Mark Legar100 (10.160.02\bullet\bulletMark Mark Legar101 (10.160.02\bullet\bulletMMark Mark Legar0.$	MR-Egger	8	5.09 (0.63,40.76)	0.18		_	>	MR-Egger	8	1.34 (0.85,2.09)	0.25		_
MMR-W1010101010101010101010100 <t< td=""><td>Weighted median</td><td>8</td><td>1.73 (1.15,2.62)</td><td>0.0092</td><td></td><td>-</td><td>-</td><td>Weighted median</td><td>8</td><td>1.31 (1.18,1.47)</td><td>9.1E-07</td><td>-</td><td></td></t<>	Weighted median	8	1.73 (1.15,2.62)	0.0092		-	-	Weighted median	8	1.31 (1.18,1.47)	9.1E-07	-	
MRR-MR-Egapt 10 27,011.00 0.0 MRR-MR-Egapt 10 100,071.01 0.0 Libility bigh offee consumption 3 17,001.00 0.0 <	MVMR-IVW	19	1.19 (0.78,1.81)	0.42		_	_	MVMR-IVW	19	1.28 (1.11,1.48)	0.00094		
Labity big to offee consumption No 3 127 (0.01.50) 0.0	MVMR-MR-Egger	19	2.78 (1.19,6.50)	0.018		_		MVMR-MR-Egger	19	1.08 (0.78,1.49)	0.66		
NW 3 127 ($0.51.50$) 0.2 NW 3 1.16 ($1.11.20$) 0.65 ($0.51.57$) 0.6 Weighed median 3 1.2 ($0.51.60$) 0.0 0	Liability to high coffee consumption							Liability to high coffee consumption					
MR-Eger 3 0.00 0.01 0.02 \bullet MR-Eger 3 1.01 0.01 \bullet Wighted median 3 1.17 0.51.40 0.02 \bullet MAR-MW 13 1.17 0.51.40 0.02 \bullet MAR-MW 13 1.51 0.02 0.01 \bullet MAR-MW 13 1.51 0.01 0.01 \bullet \bullet MAR-MW 13 1.51 0.01 0.01 \bullet \bullet MAR-MW 13 1.51 0.01 0.01 \bullet </td <td>IVW</td> <td>3</td> <td>1.27 (0.86,1.90)</td> <td>0.23</td> <td></td> <td></td> <td>_</td> <td>IVW</td> <td>3</td> <td>1.18 (1.11,1.24)</td> <td>9.6E-09</td> <td>-</td> <td></td>	IVW	3	1.27 (0.86,1.90)	0.23			_	IVW	3	1.18 (1.11,1.24)	9.6E-09	-	
Weighed median31.24 (20,81,10)0.09Holped median31.71 (10,12)2.25-0MARA-WA131.37 (20,11)0.00.000.	MR-Egger	3	0.90 (0.16,5.15)	0.92	←		>	MR-Egger	3	1.06 (0.88,1.27)	0.66	-	
MARR-MW 13 1.17 (0.9.1.42) 0.13 MAR MARK-MW 13 1.51 (0.0.1.2) 4.1E-0 MARR-MW-Egger 13 1.36 (10.0.1.6) 0.00	Weighted median	3	1.24 (0.96,1.60)	0.099				Weighted median	3	1.17 (1.09,1.25)	2.2E-05		
MAR-MR-Egger 13 136 (10.1.60) 0.02	MVMR-IVW	13	1.17 (0.95,1.42)	0.13		-		MVMR-IVW	13	1.15 (1.09,1.23)	4.1E-06	-	
High blood pressure Low HDL=cholesterol Method No. of SNPs OR (95% Cl) P Coffee consumption (cupsiday) Method No. of SNPs OR (95% Cl) P Coffee consumption (cupsiday) NV 8 0.96 (0.87,143) 0.93 Image: Consumption (cupsida y) VW 8 0.97 (0.82,116) 0.77 Image: Consumption (cupsida y) NV 8 0.96 (0.87,143) 0.93 Image: Consumption (cupsida y) VW 8 0.97 (0.82,113) 0.66 Image: Consumption (cupsida y) NV 8 0.96 (0.87,143) 0.93 Image: Consumption (cupsida y) Vieighted median 8 0.97 (0.82,113) 0.66 Vieighted median 8 1.95 (0.88,124) 0.56 Image: Consumption (cupsida y)	MVMR-MR-Egger	13	1.36 (1.03,1.80)	0.030			-	MVMR-MR-Egger	13	1.08 (1.00,1.16)	0.043		
Linema to preserve Low HD Needed No. of SNPs QR (95% C) P Colfee consumption (cups/dsy) Develop-less (cups/dsy) NW 8 0.97 (0.82.116) 0.77 M MR-Egger 8 0.57 (0.78.124) 0.26 P NMR-Egger 8 0.97 (0.82.116) 0.67 M MR-Egger 8 0.57 (0.78.124) 0.26 P MMR-Egger 8 0.97 (0.82.116) 0.67 M MR-Egger 8 1.57 (0.78.124) 0.26 P MMR-MR-Egger 19 0.90 (0.72.111) 0.26 P MVMR-MNW 19 1.01 (0.82.124) 0.56 MMR-MR-Egger 13 1.09 (0.85.115) 0.57 MV 13 1.06 (0.85.127) 0.50 MMR-MR-Egger 3 1.01 (0.82.115) 0.57 MV 3 1.06 (0.85.127) 0.50 P MMR-MR-Egger 3 1.02 (0.94.115) 0.57 MVMR-MMR MVMR-MMR 3 1.06 (0.81.17) 0.50 P MMR-MR-Egger 3 1.02 (0.94.115) 0.57 MVMR-MR M					0.20	1.0 Vids ratio	4.0					0.20 1.0 Odds ratio	4.0
Initial presure No. of SNP QR (95% C) P Method No. of SNP QR (95% C) P Coffee consumption (cupsidisy) 6 Offlee consumption (cupsidisy) Coffee consumption (cupsidisy) 0.97 (0.82,116) 0.77 INV 8 0.98 (0.87,143) 0.93 0.94 Inv 0.95 0.95 0.95 Inv 0.93 Inv Inv 0.93 0.95 Inv Inv 0.93 Inv Inv 0.93 Inv <													
Matrix Micro Mills City (c)r, Cy Image: City (c)r, Cy	Nethod	High bloc	OR (95% CI)	P				Method	Low HDL-	Cholesterol	P		
Verific Contamponent (Corporator) 0.97 (0.62,1.16) 0.77 • N/W 8 0.96 (0.67,1.43) 0.93 MR-Egger 8 1.23 (0.68,1.72) 0.28 • MR-Egger 8 1.57 (0.76,3.34) 0.26 Weighted median 8 0.97 (0.83,1.13) 0.66 • Weighted median 8 1.55 (0.89,1.24) 0.56 MMR-NW 19 0.90 (0.72,1.11) 0.32 • MVMR-NW 19 1.01 (0.82,1.24) 0.95 MMR-MR-Egger 19 1.39 (0.90,2.15) 0.14 • MVMR-NW 19 1.01 (0.82,1.24) 0.95 MMR-MR-Egger 19 1.04 (0.86,1.55) 0.97 • MVMR-NW 19 1.04 (0.86,1.37) 0.50 MMR-Seger 3 1.02 (0.84,1.55) 0.97 • MVMR-NW 3 1.06 (0.86,1.37) 0.50 MR-Egger 3 1.01 (0.53,1.61) 0.96 • MVMR-NW 3 1.06 (0.86,1.37) 0.50 MMR-NW 13 0.96 (0.86,1.56) 0.67 • MVMR-NW 13 1.06 (0.93,1.17) 0.41 <	Coffee consumption (cuns/day)			-				Coffee consumption (cups/day)			-		
Implementation Imple	IVW	8	0.97 (0.82 1 16)	0.77		¥.		IVW	8	0.98 (0.67 1 43)	0.93		
Labelity to high coffee consumption 3 1.00 (0.851.15) 0.97 MVMR-MR-Egger 19 1.06 (0.851.24) 0.55 MMRReger 19 1.39 (0.302.15) 0.14 MVMR-MR-Egger 19 1.01 (0.82,1.24) 0.95 Lability to high coffee consumption Image: Construction Image: Con	MR-Eoger	8	1.23 (0.88.1.72)	0.28				MR-Equer	8	1.57 (0.76.3.24)	0.26	Ī.	
Image: Sector of the sector	weighted median	8	0.97 (0.83 1 13)	0.66		1		-sa	8	1.05 (0.89 1 24)	0.58	1	
Immeritie 13 Description Immeritie 13 Description IVW 3 1.08 (0.981.15) 0.97 MVMR-MR-Egger 19 1.48 (0.97,228) 0.071 IVW 3 1.08 (0.981.15) 0.97 MVW 3 1.08 (0.961.137) 0.50 MR-Egger 3 1.01 (0.53.191) 0.96 MR-Egger 3 1.02 (0.34.0.07) 0.97 Weighted median 3 1.00 (0.90.110) 0.96 Weighted median 3 1.08 (0.96,122) 0.18 MMRIWR-Egger 13 0.96 (0.91,121) 0.53 MVMR-MIR-Egger 13 1.06 (0.91,121) 0.43	MVMP_IVM	10	0.90 (0.721.11)	0.00		1		MVMP_IV/M	19	1.01 (0.82 1.24)	0.95	_	
Immunicative coget 1.5 1.6 1.6 1.6 1.6 1.6 1.6 1.6 Lability to high coffee consumption Lability to high coffee consumption Lability to high coffee consumption Immunicative coget 3 1.06 (0.86,1.37) 0.50 WW 3 1.06 (0.86,1.37) 0.50 - - - - Weighted median 3 1.06 (0.95,1.10) 0.96 MR-Egger 3 1.06 (0.95,1.22) 0.18 MMR-WW 13 0.96 (0.95,1.20) 0.67 MVMR-WW 13 1.06 (0.91,1.21) 0.43 MMR-Egger 13 1.06 (0.91,1.21) 0.53 - MVMR-MR-Egger 13 1.06 (0.91,1.20) 0.36	M/MP_MP_Enger	10	1 39 (0 90 2 15)	0.14		1.	_	M/MR_MR_Free	19	1.49 (0.97 2.28)	0.071	L	_
Mining a right control outsing both	Lishility to high coffee consumption	10	1.00 (0.00,2.10)	0.14		1		Liphility to high coffee consumption	15	1.40 (0.07,2.20)	0.071	-	
MR-Egger 3 1.01 (0.53.1.91) 0.98 MR-Egger 3 1.02 (0.34.307) 0.97 Weighted median 3 1.00 (0.90.1.10) 0.96 Weighted median 3 1.06 (0.95.1.22) 0.18 MMR-NW 13 0.98 (0.821.08) 0.67 MVMR-NW 13 1.66 (0.93.1.17) 0.43 MMR-Egger 13 1.05 (0.91.121) 0.53 MVMR-MR-Egger 13 1.06 (0.91.129) 0.36	I/W	3	1.00 (0.88 1 15)	0.97		1		IVW	3	1.08 (0.86 1 37)	0.50		
Magente 1 1.00 (0.90,1.10) 0.95 Multiplied median 3 1.06 (0.95,1.22) 0.18 MMRIVW 13 0.96 (0.89,1.68) 0.67 M/MRIVW 13 1.05 (0.91,1.21) 0.43 MMRMR-Egger 13 1.05 (0.91,1.21) 0.53 M/MRMR-Egger 13 1.08 (0.91,1.22) 0.36	MR-Foger	3	1.01 (0.53.1.91)	0.98			-	MR-Enner	3	1.02 (0.34.3.07)	0.97		
MnMRINW 13 0.56 (0.51,121) 0.57 Mn/MRINW 13 1.05 (0.53,1.17) 0.43 MnMRINW 13 1.05 (0.51,121) 0.53 Mn/MRINW 13 1.06 (0.51,120) 0.36 Mn/MRINW 13 1.05 (0.51,120) 0.36	Weighted median	3	1.00 (0.90.1.01)	0.96		Ī		Weighted median	3	1.08 (0.96 1.22)	0.18	Ī	
M/MR-MR-Egger 13 1.05 (0.91,121) 0.53 0.20 1.0 40	MVMR-IVW	13	0.98 (0.89.1.02)	0.67		I		MV/MR-IV/W	13	1.05 (0.93 1.17)	0.43	Ī	
	M/MR-MR-Enger	13	1.05 (0.00,1.00)	0.53				MVMR-MR-Fager	13	1.08 (0.91 1.20)	0.36		
9.29 1.9 4.9		13	1.00 (0.01,1.21)		20	10			13	1.00 (0.91,1.29)	0.30	20 1.0	

Error bars are 95% CI. Effect estimates of MVMR are adjusted for alcohol consumption and liability to smoke initiation. Coffee consumption was measured among coffee consumers only. For liability to high coffee consumption, high coffee consumption was defined as 4 cups or more per day.